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FOR THE VISTA COLLABORATION
OBJECTIVE — The use of alteplase in patients who have had a prior stroke and concomitant
diabetes is not approved in Europe. To examine the inﬂuence of diabetes and prior stroke on
outcomes, we compared data on thrombolysed patients with nonthrombolysed comparators.
RESEARCH DESIGN AND METHODS — We selected patients with ischemic stroke
on whom we had data on age, pretreatment baseline National Institutes of Health Stroke Scale
(b-NIHSS), and 90-day outcome measures (functional modiﬁed Rankin score [mRS]) and neu-
rological measures [NIHSS]) in the Virtual International Stroke Trials Archive. We compared
outcomes between thrombolysed patients and nonthrombolysed comparators in those with and
without diabetes, those who have had a prior stroke, or both and report ﬁndings using the
Cochran-Mantel-Haenszel (CMH) test and proportional odds logistic regression analyses. We
report an age-adjusted and b-NIHSS–adjusted CMH P value and odds ratio (OR).
RESULTS — Rankin data were available for 5,817 patients: 1,585 thrombolysed patients and
4,232 nonthrombolysed comparators. A total 1,334 (24.1%) patients had diabetes, 1,898
(33.7%) patients have had a prior stroke, and 491 (8%) patients had both. Diabetes and non-
diabetes had equal b-NIHSS (median 13; P  0.3), but patients who have had a prior stroke had
higher b-NIHSS than patients who have not had a prior stroke (median 13 vs. 12; P  0.0001).
Functional outcomes were better for thrombolysed patients versus nonthrombolysed compar-
atorsamongbothnondiabetic(P0.0001;OR1.4[95%CI1.3–1.6])anddiabetic(P0.1;1.3
[1.05–1.6 ]) subjects. Similarly, outcomes were better for thrombolysed patients versus non-
thrombolysed comparators among who have not had a prior stroke (P  0.0001; 1.4 [1.2–1.6 ])
and those who have (P  0.02; 1.3 [1.04–1.6 ]). There was no interaction of diabetes and prior
stroke with treatment (P  0.8). Neurological outcomes were consistent with the mRS.
CONCLUSIONS — Outcomes from thrombolysis are better among patients with diabetes
and/or those who have had a prior stroke than in control subjects. Withholding thrombolytic
treatment from otherwise-eligible patients may not be justiﬁed.
Diabetes Care 33:2531–2537, 2010
T
hrombolytic therapy is the only
proven therapy known to enhance
outcomes in ischemic stroke pa-
tients (1,2). Its mechanism involves re-
canalization and rapid reperfusion of the
critically hypoperfused brain tissue,
which in turn restores the function of
ischemic brain parenchyma (2,3). Reper-
fusion-induced improvement in out-
comes depends on local factors in brain
tissue, such as the extent of neuronal
damage, cerebral perfusion pressure (sys-
temic blood pressure), oxidative stress,
intracellular acidosis, and mitochondrial
dysfunction (3,4). Animal studies have
shown a conﬂicting association of hyper-
glycemia with ischemic stroke (4). In-
stead, clinical studies (3–5) have largely
shown an adverse inﬂuence of hypergly-
cemia on the outcomes of nonlacunar
ischemic stroke patients. Poorer response
to thrombolysis in these patients is con-
sidered to be a result of increased plas-
minogen activator inhibitor-1 activity,
resistance to antithrombotic agents, and
higherprevalenceofatherosclerosis(3,5).
Stroke recurrence is another major prob-
lem encountered in clinical practice, and
prior stroke in patients is known to re-
duce the beneﬁts attainable from throm-
bolytictherapy(6).Becausethesepatients
are already on antithrombotic therapy,
several clinicians mostly worry about
hemorrhagic complications when admin-
istering the thrombolytic therapy. An
analysis of patients who were treated dur-
ing 0–6 h of stroke onset (n  2,184)
enrolled in ﬁve thrombolysis trials
(2,6–9) has shown that a previous stroke
and diabetes are the predictors of poor
outcome.
Owing to the concerns of poorer out-
comes in these patients if given thrombo-
lytic therapy, and two previously
unsuccessful Europe-speciﬁc thromboly-
sis trials, trialists agreed to exclude pa-
tients with diabetes or a history of stroke
when designing the European Coopera-
tive Acute Stroke Study III (ECASS III)
(1). As a result, despite encouraging re-
sultsfromtheECASSIII(1),theonlypos-
itive thrombolysis study since the
National Institute of Neurological Disor-
ders and Stroke (2), the European drug
authorities had to suggest exclusion of
these patients from receiving recombi-
nant tissue-type plasminogen activator
(rt-PA) therapy when formalizing drug-
uselabels(10).Useofalteplaseinpatients
having prior stroke and concomitant dia-
betes is not approved in Europe (10). Re-
gardless, physicians still treat diabetic
patients in routine clinical practice or re-
search settings (11).
In the current scenario, an ideal ap-
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ized controlled trial and examine the
inﬂuenceofthrombolytictherapyonout-
comes in patients who have diabetes and
havehadapreviousstroke.Toourknowl-
edge, there are no plans of any trial group
to conduct such a trial; therefore, we
planned for an alternative approach. We
decided to examine outcomes of patients
who received rt-PA against those who did
not, from the data of the neuroprotection
trials conducted between1998 and 2007
and obtained these data from the Virtual
International Stroke Trials Archive
(VISTA). Using an analytical approach rec-
ommended by the European Medicines
Agency (EMEA), we compared outcomes
amongpatientswhohavediabetes,hadpre-
vious strokes, and a combination thereof.
RESEARCH DESIGN AND
METHODS
Data source and patients
We collated the demographics, clinical
data,andmeasuresoffunctionaloutcome
from neuroprotection trials conducted in
the period between 1998 and 2007, held
within the VISTA (12). All trials had nec-
essary review board and regulatory ap-
provals, and patients consented to
participation; only anonymized data are
held by the VISTA (12). We sought data
from the VISTA deriving from trials in
which the investigational neuroprotec-
tion agent was neither vasoactive nor in-
terfered with clotting or from placebo
groups. We excluded any patient who
had cerebral hemorrhage or stroke of un-
determined etiology. To avoid dual pub-
lication, we excluded patients who may
have been enrolled in the Safe Implemen-
tation of Thrombolysis in Stroke-
Monitoring Study, as determined from
theircountryanddateofenrollment(13).
Finally, we excluded patients lacking our
chosen outcome measure (90-day modi-
ﬁed Rankin score [mRS]) or secondary
outcome (90-day National Institutes of
Health Stroke Scale [NIHSS] score). Pa-
tientswhodiedwithin90daysweregiven
an mRS score of 6 and were categorized
separately for NIHSS analysis.
Statistical analysis
We compared the outcome between pa-
tients who received thrombolysis and
nonthrombolysed control subjects
among patients who had diabetes, prior
stroke,oracombinationofboth.Foreach
contrast, we compared the overall distri-
bution of all seven categories of day-90
mRSscoresofthetwogroups(i.e.,from0
[asymptomatic] through 5 [bedbound
and completely dependent] to 6 [dead]).
The EMEA points to consider for report-
ing trials allow for use of the full distribu-
tion of the mRS but suggest that this may
be supported by a secondary analysis of a
second outcome measure such as the
NIHSS (14). For analysis of our support-
ing end point, NIHSS, we grouped adja-
cent scores into the following categories:
0 (no measurable deﬁcit), 1–4, 5–8,
9–12, 13–16, 17–20, 21–24, and 25
(most severe neurological deﬁcit) or
death. The distribution of patients across
Figure 1—Baseline description of the data derived from VISTA for the analyses.
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tween the groups as for mRS.
To test for a signiﬁcant association of
outcome distribution with thrombolysis
exposure, we used the Cochran-Mantel-
Haenszel [CMH] statistic, adjusting for
both age and baseline NIHSS as continu-
ous variables (15). This nonparametric
approach avoids invoking an assumption
of proportional odds in which there
should be a common odds ratio (OR)
across all cut points on the ordinal out-
come scale, and we consider that the
CMH test provides the most conservative
estimate of statistical signiﬁcance (15–
17). However, it does not express the ex-
tent of the association. For this, we
applied logistic regression analysis, also
adjusted for age and baseline NIHSS, to
estimate the OR under the assumption of
proportional odds and its associated 95%
CI.
Our choice of baseline factors for ad-
justment was based on two inﬂuences.
First,ageandbaselineseverityarethetwo
most powerful prognostic factors for
stroke and are usually included in out-
come distribution analyses (18). Second,
ageandNIHSSdatawereavailableforour
entire sample, whereas other factors of
potential interest were incomplete. How-
ever,wealsoundertookasensitivityanal-
ysisbyconsideringthecombinedeffectof
the variables that differed signiﬁcantly at
baseline, but if this resulted in excessive
diminution of our sample, we did not
quote the ﬁndings.
Our objective was mainly to under-
take ordinal distribution or “shift” analy-
sis,whichisanefﬁcientendpointanalytic
technique recommended by the EMEA
(19). Shift analysis is considered better
than dichotomization of end point mea-
sures, although there are differences of
opinion(16,17,20–22).Dichotomization
is criticized for the statistical information
it discards (i.e., loss of power), and shift
analysis is especially useful when the
treatment effect is mild and/or uniform
across all Rankin categories (16,20,23).
For comparison with prior randomized
trial and registry reports, however, we
also present dichotomized analyses of
mRS, based on excellent outcome (mRS
0–1), favorable outcome (mRS 0–2), and
survival; these analyses are expressed as
ORs adjusted for age and b-NIHSS, as for
theprimaryandsecondaryendpoints.To
remain consistent with the current age
criteria of the EMEA, we examined if the
interaction of age with t-PA had inﬂuence
over outcomes. In addition, we estimated
T
a
b
l
e
1
—
T
a
b
l
e
s
h
o
w
s
t
h
e
b
a
s
e
l
i
n
e
c
h
a
r
a
c
t
e
r
i
s
t
i
c
s
o
f
t
h
e
p
a
t
i
e
n
t
s
i
n
t
h
e
V
I
S
T
A
c
l
a
s
s
i
ﬁ
e
d
b
y
t
h
e
p
r
e
s
e
n
c
e
o
f
d
i
a
b
e
t
e
s
,
p
r
e
s
e
n
c
e
o
f
p
r
i
o
r
s
t
r
o
k
e
,
a
n
d
p
r
e
s
e
n
c
e
o
f
p
r
i
o
r
s
t
r
o
k
e
a
n
d
c
o
n
c
o
m
i
t
a
n
t
d
i
a
b
e
t
e
s
G
r
o
u
p
o
f
d
i
a
b
e
t
i
c
p
a
t
i
e
n
t
s
G
r
o
u
p
o
f
p
r
i
o
r
s
t
r
o
k
e
p
a
t
i
e
n
t
s
G
r
o
u
p
o
f
c
o
n
c
o
m
i
t
a
n
t
d
i
a
b
e
t
e
s
a
n
d
p
r
i
o
r
s
t
r
o
k
e
*
A
l
t
e
p
l
a
s
e
N
o
a
l
t
e
p
l
a
s
e
A
l
t
e
p
l
a
s
e
N
o
a
l
t
e
p
l
a
s
e
A
l
t
e
p
l
a
s
e
N
o
a
l
t
e
p
l
a
s
e
A
g
e
*
*
M
e
a
n
6
9
.
5
(
1
0
.
9
)
,
n

3
4
2
7
0
.
3
(
1
0
.
8
)
,
n

9
9
2
7
0
.
6
(
1
2
.
6
)
,
n

3
1
9
7
3
.
2
(
1
0
.
9
)
,
n

1
,
5
7
9
7
1
.
2
(
1
0
)
,
n

8
6
7
1
.
8
(
9
.
8
)
,
n

4
0
5
M
e
d
i
a
n
7
1
(
3
3
–
9
8
)
7
2
(
3
0
–
9
6
)
7
3
(
2
1
–
9
8
)
7
5
(
3
0
–
1
0
1
)
7
3
(
4
6
–
9
8
)
7
3
(
3
7
–
9
0
)
P

0
.
2
P

0
.
0
0
0
2
P

0
.
6
S
e
x
(
m
a
l
e
)
1
9
8
/
3
4
2
(
5
7
.
9
%
)
5
3
2
/
9
9
2
(
5
3
.
6
%
)
1
8
0
/
3
1
9
(
5
6
.
4
%
)
8
2
2
/
1
,
5
7
9
(
5
2
.
1
%
)
5
4
/
8
6
(
6
2
.
8
%
)
2
1
2
/
4
0
5
(
5
2
.
3
%
)
P

0
.
1
7
P

0
.
2
P

0
.
0
7
B
a
s
e
l
i
n
e
N
I
H
S
S
1
3
(
5
–
3
0
)
1
3
(
2
–
2
9
)
1
3
(
3
–
3
0
)
1
2
(
2
–
3
7
)
1
3
.
5
(
5
–
3
0
)
1
2
(
2
–
2
9
)
P

0
.
0
1
P

0
.
0
2
P

0
.
0
3
A
t
r
i
a
l
ﬁ
b
r
i
l
l
a
t
i
o
n
8
2
/
3
4
2
(
2
4
%
)
2
5
6
/
9
9
2
(
3
4
.
5
%
)
8
2
/
3
1
2
(
2
6
.
3
%
)
5
0
1
/
1
,
4
9
4
(
3
3
.
5
%
)
1
8
/
8
6
(
2
0
.
9
%
)
1
0
5
/
4
0
5
(
2
5
.
9
%
)
P

0
.
0
5
P

0
.
0
0
9
P

0
.
3
H
y
p
e
r
t
e
n
s
i
o
n
2
7
8
/
3
4
2
(
8
1
.
3
%
)
7
9
5
/
9
9
2
(
8
0
.
1
%
)
2
4
0
/
3
1
2
(
7
6
.
9
%
)
1
,
1
6
2
/
1
,
4
9
4
(
7
7
.
8
%
)
7
6
/
8
6
(
8
8
.
4
%
)
3
3
2
/
4
0
5
(
8
2
%
)
P

0
.
6
P

0
.
7
P

0
.
2
P
r
i
o
r
u
s
e
o
f
a
n
t
i
p
l
a
t
e
l
e
t
s
1
2
0
/
2
4
1
(
4
9
.
8
%
)
1
4
5
/
3
4
8
(
4
1
.
7
%
)
1
1
9
/
1
8
6
(
6
4
%
)
1
6
8
/
3
4
9
(
4
8
.
1
%
)
3
7
/
5
1
(
7
2
.
5
%
)
6
2
/
1
0
5
(
5
9
.
0
%
)
P

0
.
0
5
3
P

0
.
0
0
1
P

0
.
0
9
%
P
r
i
o
r
a
n
t
i
c
o
a
g
u
l
a
n
t
s
1
7
/
2
4
1
(
7
.
1
%
)
4
4
/
3
4
8
(
1
2
.
6
%
)
1
8
/
1
8
6
(
9
.
7
%
)
7
7
/
3
4
9
(
2
2
.
1
%
)
5
/
5
1
(
9
.
8
%
)
2
0
/
1
0
5
(
1
9
.
0
%
)
P

0
.
0
3
P

0
.
0
5
P

0
.
1
U
s
e
o
f
a
n
t
i
t
h
r
o
m
b
o
t
i
c
s
1
2
9
/
2
4
1
(
5
3
.
5
%
)
1
7
3
/
3
4
8
(
4
9
.
7
%
)
1
2
8
/
1
8
6
(
6
8
.
8
%
)
2
2
5
/
3
4
9
(
6
4
.
5
%
)
3
8
/
5
1
(
7
4
.
5
%
)
7
2
/
1
0
5
(
6
8
.
6
%
)
P

0
.
0
4
P

0
.
3
P

0
.
4
M
y
o
c
a
r
d
i
a
l
i
n
f
a
r
c
t
i
o
n
9
4
/
3
4
2
(
2
7
.
5
%
)
2
0
2
/
9
9
2
(
2
0
.
4
%
)
7
9
/
3
1
2
(
2
5
.
3
%
)
2
9
9
/
1
,
4
9
4
(
2
0
%
)
2
6
/
8
6
(
3
0
.
2
%
)
8
7
/
4
0
5
(
2
1
.
5
%
)
P

0
.
0
0
9
P

0
.
0
4
7
P

0
.
1
C
o
n
g
e
s
t
i
v
e
c
a
r
d
i
a
c
f
a
i
l
u
r
e
4
6
/
2
7
2
(
1
6
.
9
%
)
5
0
/
3
7
4
(
1
3
.
4
%
)
4
0
/
1
9
7
(
2
0
.
3
%
)
4
5
/
3
5
9
(
1
2
.
5
%
)
1
1
/
5
3
(
2
0
.
7
%
)
1
3
/
1
1
0
(
1
1
.
8
%
)
P

0
.
2
P

0
.
0
2
P

0
.
2
P
v
a
l
u
e
r
e
f
e
r
s
t
o
t
h
e
c
o
m
p
a
r
i
s
o
n
b
e
t
w
e
e
n
t
h
e
t
r
e
a
t
e
d
a
n
d
n
o
n
t
r
e
a
t
e
d
g
r
o
u
p
c
o
r
r
e
s
p
o
n
d
i
n
g
t
o
e
a
c
h
v
a
r
i
a
b
l
e
.
*
T
h
e
g
r
o
u
p
c
o
m
p
r
i
s
i
n
g
d
i
a
b
e
t
e
s
a
n
d
p
r
i
o
r
s
t
r
o
k
e
w
a
s
c
o
m
p
a
r
e
d
s
p
e
c
i
ﬁ
c
a
l
l
y
a
g
a
i
n
s
t
t
h
o
s
e
p
a
t
i
e
n
t
s
w
h
o
h
a
d
n
e
i
t
h
e
r
o
f
t
h
e
t
w
o
f
a
c
t
o
r
s
.
*
*
A
g
e
i
s
d
e
s
c
r
i
b
e
d
w
i
t
h
m
e
a
n
a
n
d
S
D
(
a
b
o
v
e
)
a
n
d
m
e
d
i
a
n
(
r
a
n
g
e
)
(
b
e
l
o
w
)
.
Mishra and Associates
care.diabetesjournals.org DIABETES CARE, VOLUME 33, NUMBER 12, DECEMBER 2010 2533Figure2—Forestplots(AandB)andbardiagrams(C)showingoutcomesintheapprovedpopulation(absenceofdiabetesorpriorstrokes)andtheaffected
population(presenceofdiabetesorpriorstroke).Alloutcomesareoutcomesonday90afterthestroke.Excellentoutcomesrefertom-RS0-1andfavorable
outcomestom-RS0-2.NeurologicaloutcomesrefertotheNIHSSscoresonday90.Analysesforneurologicaloutcomeswereundertakenusingproportional
odds logistic regression analyses. NIHSS by day 90 were combined into categories as 0–4, 5–8, 9–12, 13–16, 17–20, 21–24, and 25, and distributions
were compared in a manner similar to Rankin scores.
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logisticregressionanalysisforpatientsbe-
longing to age-group 80 years.
ORs in our analysis express the com-
mon odds of an improved distribution of
outcome in association with alteplase
treatment. CMH and logistic regression
analysis were undertaken using SAS 9.2
softwareandotheranalysesbyStatsDirect
software. Reliable information on symp-
tomatic hemorrhage was not available be-
cause posttreatment imaging was not
routinely applied in neuroprotection tri-
als to patients who had not been treated
with alteplase.
RESULTS
Patient sample
We collated data on 9,665 patients, of
whom 5,342 (59%) were enrolled from
non-European sites. To avoid dual publi-
cation with the Safe Implementation of
Thrombolysis in Stroke-Monitoring
Study (13), we excluded 2,789 patients
(28%) enrolled from European sites be-
tween 2002 and 2006 and 177 patients
for whom we lacked information on na-
tionality. Complete data were available
for analysis of mRS in 5,817 patients and
on NIHSS in 5,715 (Fig. 1).
All stroke patients were treated as per
institutional practice and stroke guide-
lines acceptable at the point of trial con-
duct.Monitoringforprotocolcompliance
was undertaken on behalf of sponsors for
these trials. This implies that where
thrombolysis was administered, this was
in accordance with marketing authoriza-
tion for the relevant country (i.e., that
treatment commenced within3ho f
stroke onset); however, the onset to treat-
ment delay is not recorded for thrombol-
ysis in these trials. Our data derived
mainly from Northern American (60%),
European (16%), and Australasian (13%)
centers. Baseline characteristics are
shown in Table 1. Of 5,817 patients with
mRS outcome data, 1,585 (27.2%) re-
ceived thrombolysis.
Analysis of outcomes
We examined the outcomes in patients
with diabetes, those who have had prior
strokes,andtheircombinations.Findings
are shown in Fig. 2.
Inaproportionaloddslogisticregres-
sion analysis adjusting for age and base-
line NIHSS, we did not ﬁnd any
interaction of diabetes (P  0.49), prior
stroke (P  0.72), and diabetes and prior
stroke (P  0.8) with use of rt-PA. For
each of the analyses above, we also con-
sidered the subgroup of patients aged
80 years and also sought evidence of
anyinteractionwithage.Wefailedtoﬁnd
evidence of a differential effect or interac-
tion with age.
CONCLUSIONS — Our analysis re-
conﬁrms occurrence of improved out-
comes among patients who do not have
diabetes and prior stroke, with a signiﬁ-
cant odds of 1.4. These odds were com-
parable to the odds obtained from large
thrombolysis trials (24), which allowed
ustoanchorourﬁndingsonpatientshav-
ing both diabetes and previous stroke
with the trial data. We showed a signiﬁ-
cant association of improved outcomes
with the use of thrombolytic therapy in
Figure 2—Continued.
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stroke” and then also showed that there
were no interactions of the diabetes and
prior strokes with the use of thrombolytic
therapy. However, we failed to conﬁrm
statistical signiﬁcance for a small group of
patients who concomitantly had a previ-
ous stroke and diabetes (OR 1.5 [95% CI
0.98–2.3]). We attribute this to a type 2
error in this subgroup, namely a smaller
sample size (n  491). Our ﬁndings from
shiftanalyseswerealsosupportedbysim-
ilar results from the analyses of dichoto-
mized outcomes.
These ﬁndings can be generalized not
only because of the comparable odds to
those obtained from the large trials data
(24) but also because our results were
replicated on another analysis involving
the comparison of thrombolysed patients
(intheSafeImplementationofThrombol-
ysis in Stroke-Monitoring Study dataset)
with the nonthrombolysed control sub-
jects (from the VISTA) (25). In addition,
we had supportive ﬁndings from analyses
of our group (M.K.) for the Helsinki
Thrombolysis Register. Here, from 1,200
consecutively treated patients, complete
information was available for 1,104 pa-
tients, and 51% of patients were treated
despite license contraindications. The
analysis of 26 patients aged 80 years
who had both diabetes and previous
stroke suggested poorer favorable out-
comes (mRS 0–2) in univariate analysis
when compared with those treated ac-
cording to the European license of alte-
plase but not in multivariate analysis.
These patients had more symptomatic in-
tracerebral hemorrhages than those
treated on label in univariate analysis, but
95% CI was not signiﬁcant and in a mul-
tivariate analysis there was no trend for
symptomatic hemorrhage. We could not
however examine the symptomatic brain
hemorrhages in our VISTA patients, as
our data were derived from neuroprotec-
tion trials, which had not routinely ob-
tained imaging information of the
untreated patients.
We based our conclusions on ad-
justed analyses, adjusting for age and
baseline NIHSS, because prognostic vari-
ables differed at baseline, and age and
baseline severity have an established in-
ﬂuence on stroke outcomes (18). How-
ever, we could not adjust for all variables,
as data were incomplete. Despite robust
analyses and adjustment for important
variables,weacknowledgethatarandom-
ized study would have the best design.
But there are no such studies conducted
yet or any that are ongoing. Ours is the
onlyanalysesavailablethatisbasedonthe
largest dataset on thrombolysed patients
available to date. It uses an analytic ap-
proach recommended by the EMEA and
replicatesﬁndingsoffunctionaloutcomes
on neurological outcomes.
We know that patients with premor-
bid mRS 1 were excluded from the
VISTA trials, but the prestroke functional
status of individual patients were not re-
corded in VISTA. Hence, it is likely that
anyeffectofprestrokedisabilityinthepa-
tients having prior stroke(s) would only
lead to an underestimation treatment ef-
fect in this analyses.
We agree that there could be differ-
ences on outcomes owing to center spe-
ciﬁc effects on treatment of patients. This
would, however, occur if the patients
were part of routine clinical care and not
enrolled in rigorously controlled clinical
trials. Because our patients were enrolled
in neuroprotection clinical trials during
1998–2007, we assume that they all re-
ceived the best standard of care at each
participating center. A total of 60% of our
patients were from American centers
where the thrombolytic therapy was ap-
proved soon after the NINDS results were
published in 1995 (2). During next years,
even other centers (including European
centers [16% patients]) practiced throm-
bolytic therapy based on clinicians’
choice (13). In 2002, the alteplase was
approved in Europe as well. This would
imply that all those stroke patients who
were eligible for thrombolysis in physi-
cian’s opinion received therapy. How-
ever, we could not adjust for centers, as
center-speciﬁc information was missing
in our dataset.
Finally, one must consider that anal-
yses like these are based on probabilistic
models where level of signiﬁcance is arbi-
trarily chosen (and conventionally set at
5%), and the decision to thrombolyse is
left to the clinicians who determine their
own limits regarding taking chances
while offering the therapy. The group of
patients having concomitant diabetes and
previous strokes missed statistical signiﬁ-
cance but had a favorable point estimate
of 1.5. Had we considered a higher level
of signiﬁcance, our results would have
been signiﬁcant for outcomes among all
subgroups of patients.
In summary, our analysis shows im-
provedoutcomesamongpatientswithdi-
abetes,thosewhohavehadapriorstroke,
and those with diabetes and/or prior
stroke,thoughmarginallyfailedtoshowa
statistically signiﬁcant improvement in
the patients who had both diabetes and a
priorstroketogether.Wehoweverbelieve
that a potential beneﬁt might exist for the
combined group too, and withholding a
proven therapy among these patients
would not be justiﬁed. Treatment may be
offered to a carefully selected patient, and
trialists should now be encouraged to
considerexaminingthesepatientsbycon-
ductingarandomizedcontrolledtrial.We
recommend that withholding treatment
from these patients is unjustiﬁed.
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